Despite broad application of these models in predicting peptide targets for CD8+ T cell responses in both cancer and infection settings, there is no systematic comparative analysis of features associated to cancer versus pathogenic peptide immunogenicity [21]. The gene discussed is CD8A; the disease is infection.